Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation

Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Endocrinol
Hoofdauteurs: Pöll, Florian, Lehmann, Diana, Illing, Susann, Ginj, Mihaela, Jacobs, Stefan, Lupp, Amelie, Stumm, Ralf, Schulz, Stefan
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Endocrine Society 2010
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/
https://ncbi.nlm.nih.gov/pubmed/20051480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items